Junshi/Lilly Dual Antibody Treatment Approved in US to Treat COVID-19

Junshi Biosciences and Eli Lilly announced their dual mAb treatment was approved in the US to treat COVID-19 under emergency use rules. In a US Phase II/III trial, a combination of Junshi's etesevimab (JS016) and Lilly's bamlanivimab (LY-CoV555) reduced the risk of COVID-19 hospitalizations and death by 70% in newly diagnosed patients. It is indicated for patients with mild to moderate COVID-19 aged 12 and older who are at high risk for progressing to severe COVID-19 and/or hospitalization. More details.... Stock Symbols: (HK: 1877; SHA: 688180) (NYSE: LLY) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.